Gene symbol | CXCL12 | Synonyms | IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1 | Type of gene | protein-coding |
Chromosome | 10 | Map location | 10q11.21 | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
Description | C-X-C motif chemokine ligand 12 |
GTO ID | GTC1364 |
Trial ID | NCT01194934 |
Disease | Lymphoma |
Altered gene | CXCL-12 |
Therapeutic/Target gene | Target gene |
Therapy | Aptamer |
Treatment | NOX-A12|olaptesed pegol |
Phase | Phase1 |
Recruitment status | Completed |
Title | A Single Center, Open-label, Repeated Dose, Phase I Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics and the Effect on Mobilization of Hematopoietic Stem Cells of NOX-A12 Alone and in Combination With Filgrastim |
Year | 2010 |
Country | Germany |
Company sponsor | TME Pharma AG |
Other ID(s) | SNOXA12C101|2010-020937-14 |
Cohort1: NOX-A12_dose level1 | |||||||
|
|||||||
Cohort2: NOX-A12_dose level2 | |||||||
|
|||||||
Cohort3: Filgrastim | |||||||
|
|||||||
Cohort4: NOX-A12_Filgrastim | |||||||
|